Tag: Mylan pharmaceuticals

A Tale of Restasis: Misadventures of Sovereign Immunity

Allergan’s “Restasis®” is a branded ophthalmic cyclosporine emulsion, for the treatment of chronic dry eye, with annual sales of nearly $1.5 billion. Original patent covering the Restasis formulation (US 5,474,979), was set to expire in 2014. In an attempt to protect its Restasis franchise, Allergan filed more patents, covering the “specific formulation and the method … Continue reading A Tale of Restasis: Misadventures of Sovereign Immunity

Read more »